ALLO - Allogene Therapeutics GAAP EPS of -$0.66 beats by $0.04 revenue of $0.05M misses by $0.01M
- Allogene Therapeutics press release ( NASDAQ: ALLO ): Q4 GAAP EPS of -$0.66 beats by $0.04 .
- Revenue of $0.05M misses by $0.01M .
- The Company expects a decrease in cash, cash equivalents, and investments of approximately $250 million in 2023. Based on current expectation, the Company expects the cash runway to be sufficient to fund operations into 2025.
- GAAP Operating Expenses are expected to be approximately $350 million, including estimated non-cash stock-based compensation expense of approximately $90 million. T
For further details see:
Allogene Therapeutics GAAP EPS of -$0.66 beats by $0.04, revenue of $0.05M misses by $0.01M